Headlines about Vital Therapies (NASDAQ:VTL) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vital Therapies earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.5035298170155 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities research analysts have recently issued reports on VTL shares. BidaskClub raised Vital Therapies from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, March 17th. Finally, ValuEngine raised Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 28th.
VTL stock traded up $0.10 during mid-day trading on Thursday, hitting $6.45. The stock had a trading volume of 233,778 shares, compared to its average volume of 181,752. Vital Therapies has a 1-year low of $2.25 and a 1-year high of $7.30. The firm has a market cap of $281.75, a P/E ratio of -4.92 and a beta of 4.26.
TRADEMARK VIOLATION NOTICE: This article was first reported by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://baseballnewssource.com/2018/04/05/vital-therapies-vtl-earning-somewhat-positive-media-coverage-accern-reports/2028967.html.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient's own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.